Merck: promising results for pneumococcal vaccine -November

Merck today announced the results of a Phase 3 trial evaluating V116, its investigational 21-valent pneumococcal conjugate vaccine specifically designed to protect adults. In adults aged 50 and over ,...

Related Keywords

Eliav Barr , Merck Research Laboratories , Head Of Global Clinical Development , Senior Vice President , Global Clinical Development , Chief Medical Officer , Merck Research , Markets ,